Synairgen plc Holding(s) in Company (6346S)
June 26 2018 - 7:05AM
UK Regulatory
TIDMSNG
RNS Number : 6346S
Synairgen plc
26 June 2018
Synairgen plc
('Synairgen' or the 'Company')
Holding in Company
Southampton, UK: Synairgen plc (LSE: SNG), the respiratory drug
discovery and development company, announces that it was today
informed that Leonard Licht, a private investor, now holds
7,700,000 ordinary shares of 1 pence each in the capital of the
Company through his Choice Bespoke SIPP.
This represents 8.48% of the total voting rights of the
Company.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Stephen Norcross, (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Sukaina Virji / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into clinical development. The
BioBank of human samples is used in these models to increase
confidence in the likelihood of successful drug development.
Synairgen is currently running a two-part Phase II trial
evaluating SNG001, the Company's wholly-owned inhaled interferon
beta (IFN-beta) therapeutic candidate. The Phase II trial, called
SG015, has been designed to assess the safety of SNG001 in COPD
patients and its clinical benefit in these patients when they have
a cold or flu infection, a major driver of COPD exacerbations.
Core to Synairgen's business strategy is the realisation of
value via licensing transactions. In August 2015 the Company
entered into a collaboration with Pharmaxis to develop an oral
LOXL2 inhibitor to reduce fibrosis in patients with idiopathic
pulmonary fibrosis (IPF). In December 2017 the collaboration
agreement was amended as Pharmaxis took on full responsibility for
the programme, with Synairgen receiving a GBP5 million upfront
payment and circa 17% of any future partnering proceeds from all
fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information
about Synairgen, please see www.synairgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
HOLLLFIFRVIRFIT
(END) Dow Jones Newswires
June 26, 2018 08:05 ET (12:05 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2023 to Apr 2024